{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:32:02Z","timestamp":1787668322036,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vph.2020.106679","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:17:25Z","timestamp":1588825045000},"page":"106679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves"],"prefix":"10.1016","volume":"130","author":[{"given":"Ewa","family":"Wypasek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Natorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kopytek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Gaw\u0119da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Kapusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Madeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Iwaniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Kapelak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2020.106679_bb0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.115.014846","article-title":"Population-wide trends in aortic stenosis incidence and outcomes","volume":"131","author":"Bonow","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2020.106679_bb0010","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease The Task Force for the Managementof Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2020.106679_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2009.03.108","article-title":"Molecular and cellular mechanisms of aortic stenosis","volume":"135","author":"Yetkin","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2020.106679_bb0020","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.ATV.0000227513.13697.ac","article-title":"Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more)","volume":"26","author":"O\u2019Brien","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2020.106679_bb0025","doi-asserted-by":"crossref","first-page":"e006339","DOI":"10.1161\/JAHA.117.006339","article-title":"Valve Interstitial Cells: The Key to Understanding the Pathophysiology of Heart Valve Calcification","volume":"6","author":"Rutkovskiy","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.vph.2020.106679_bb0030","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/ATVBAHA.117.310082","article-title":"PAR2 (protease-activated receptor 2) deficiency attenuates atherosclerosis in mice","volume":"38","author":"Jones","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"Suppl. 2","key":"10.1016\/j.vph.2020.106679_bb0035","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.thromres.2012.02.028","article-title":"Tissue factor-driven thrombin generation and inflammation in atherosclerosis","volume":"129","author":"ten Cate","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2020.106679_bb0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1538-7836.2012.04782.x","article-title":"The impact of blood coagulability on atherosclerosis and cardiovascular disease","volume":"10","author":"Loeffen","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2020.106679_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/cvr\/cvp066","article-title":"Is thrombin a key player in the \u2018coagulation-atherogenesis\u2019 maze?","volume":"82","author":"Borissoff","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2020.106679_bb0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","author":"Hara","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2020.106679_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10557-012-6411-3","article-title":"The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis","volume":"26","author":"Kadoglou","year":"2012","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.vph.2020.106679_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/jpet.112.194837","article-title":"The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice","volume":"343","author":"Lee","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2020.106679_bb0065","doi-asserted-by":"crossref","first-page":"432080","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.vph.2020.106679_bb0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"On behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2020.106679_bb0075","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS trial","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2020.106679_bb0080","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2019.01.043","article-title":"Oral anticoagulation therapy and progression of calcific aortic valve stenosis","volume":"73","author":"Tastet","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2020.106679_bb0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.20452\/pamw.791","article-title":"Evidence for tissue factor expression in aortic valves in patients with aortic stenosis","volume":"119","author":"Natorska","year":"2009","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.vph.2020.106679_bb0090","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH10-09-0612","article-title":"Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties","volume":"105","author":"Natorska","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2020.106679_bb0095","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-07-0455","article-title":"Factor XIII expression within aortic valves and its plasma activity in patients with aortic stenosis: association with severity of disease","volume":"108","author":"Kapusta","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2020.106679_bb0100","doi-asserted-by":"crossref","first-page":"C29","DOI":"10.1152\/ajpcell.00137.2007","article-title":"Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis","volume":"294","author":"Meng","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.vph.2020.106679_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.vph.2020.106679_bb0110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2020.106679_bb0115","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1006\/meth.2001.1261","article-title":"An overview of real-time quantitative PCR: applications to quantify cytokine gene expression","volume":"25","author":"Giulietti","year":"2001","journal-title":"Methods"},{"issue":"Suppl. 4","key":"10.1016\/j.vph.2020.106679_bb0120","first-page":"57","article-title":"Tissue factor expressed by aortic valve interstitial cells is able to generate thrombin in vitro","author":"Breyne","year":"2012","journal-title":"Arch Cardiovasc Dis."},{"key":"10.1016\/j.vph.2020.106679_bb0125","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1172\/JCI12980","article-title":"Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival","volume":"107","author":"Denhardt","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2020.106679_bb0130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.atherosclerosis.2010.07.047","article-title":"Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration","volume":"213","author":"Breyne","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2020.106679_bb0135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2020.106679_bb0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/14728222.2011.553608","article-title":"Blood coagulation factor Xa as an emerging drug target","volume":"15","author":"Borensztajn","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.vph.2020.106679_bb0145","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/0003319719840861","article-title":"Nonhemostatic activities of factor Xa: are there pleiotropic effects of anti-FXa direct Oral anticoagulants?","volume":"70","author":"Papadaki","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.vph.2020.106679_bb0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijcard.2018.11.119","article-title":"Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor","volume":"278","author":"Di Lullo","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2020.106679_bb0155","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1038\/s41598-019-40602-w","article-title":"Targeting coagulation factor Xa promotes regression of advanced atherosclerosis in Apolipoprotein-E deficient mice","volume":"9","author":"Posthuma","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2020.106679_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2017.12.037","article-title":"Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury","volume":"820","author":"Hara","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2020.106679_bb0165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5114\/aoms.2014.40742","article-title":"Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice","volume":"10","author":"Pingel","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.vph.2020.106679_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055784","article-title":"Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner","volume":"8","author":"Borissoff","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2020.106679_bb0175","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2353\/ajpath.2007.070251","article-title":"The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology","volume":"171","author":"Liu","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vph.2020.106679_bb0180","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2353\/ajpath.2009.080750","article-title":"Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential","volume":"174","author":"Chen","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.vph.2020.106679_bb0185","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12438","article-title":"Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE\u2212\/\u2212 mice","volume":"36","author":"Rattazzi","year":"2018","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.vph.2020.106679_bb0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.carpath.2005.01.002","article-title":"Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis","volume":"14","author":"Kaden","year":"2005","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.vph.2020.106679_bb0195","doi-asserted-by":"crossref","first-page":"32659","DOI":"10.1038\/srep32659","article-title":"Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice","volume":"6","author":"Jung","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2020.106679_bb0200","first-page":"875","article-title":"Profile and localization of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in human heart valves","volume":"11","author":"Dreger","year":"2002","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.vph.2020.106679_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0021-9150(03)00284-3","article-title":"Interleukin-1_ promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis","volume":"170","author":"Kaden","year":"2003","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1016\/j.vph.2020.106679_bb0210","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/eurheartj\/ehi248","article-title":"Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors","volume":"26","author":"Fondard","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2020.106679_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: mechanisms of production and implications in disease","volume":"15","author":"Jones","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.vph.2020.106679_bb0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2017.07.005","article-title":"Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases","volume":"264","author":"Damen","year":"2017","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.vph.2020.106679_bb0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/JLB.MR1117-457R","article-title":"Interleukin-34, a comprehensive review","volume":"104","author":"Baghdadi","year":"2018","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.vph.2020.106679_bb0230","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1073\/pnas.0813334106","article-title":"IL-32-dependent effects of IL-1beta on endothelial cell functions","volume":"106","author":"Nold-Petry","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2020.106679_bb0235","first-page":"131","article-title":"Interleukin-32: a cytokine and inducer of TNFalpha","volume":"22","author":"Kim","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.vph.2020.106679_bb0240","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ijcard.2014.07.252","article-title":"Characterisation of novel cytokines in human atherosclerotic plaque","volume":"176","author":"Xia","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2020.106679_bb0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1684\/ecn.2018.0407","article-title":"Interleukin-32 plays an essential role in human calcified aortic valve cells","volume":"29","author":"Tsai","year":"2018","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.vph.2020.106679_bb0250","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2020.106679_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after Transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189120300203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189120300203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:18:46Z","timestamp":1761527926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189120300203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":51,"alternative-id":["S1537189120300203"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2020.106679","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2020.106679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106679"}}